Sodium-glucose co-transporter 2 inhibitors beyond diabetes

Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Dimity L, Rofail, Serena, Atherton, John J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427625/
https://www.ncbi.nlm.nih.gov/pubmed/36110166
http://dx.doi.org/10.18773/austprescr.2022.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427625/
https://www.ncbi.nlm.nih.gov/pubmed/36110166
http://dx.doi.org/10.18773/austprescr.2022.036

Ejemplares similares